Characteristics (n = 59) | NIMV failure (n = 30) | NIMV success (n = 29) | P |
---|---|---|---|
Age (years) | 50.2 (± 16.7) | 53.4 (± 17.4) | 0.48 |
Sex | 17 (56.7%) | 14 (48.3%) | 0.51 |
Lactate | 1.4 (1.1–3.7) | 1.4 (1.1–2.2) | 0.63 |
PaO2 upon inclusion (mmHg) | 86.1 (73.7–115.9) | 80.2 (74.2–109) | 0.57 |
P/F upon inclusion | 266.5 (222.8–336.3) | 275 (243.5–335) | 0.77 |
SaO2 | 90 (86.5–95) | 92 (90–96.5) | 0.11 |
Overall leukocyte count (cells/mm3) | 1020 (150–4233) | 1794 (650–9210) | 0.07 |
CRP | 261.6 (128.5–361.6) | 169.3 (99.5–251.7) | 0.09 |
RR (rpm) | 34 (29–39) | 29 (27.5–34) | 0.042 |
APACHE II | 21 (17–27) | 21 (17.5–24) | 0.53 |
SAPS 3 | 64.5 (53.7–71.2) | 63 (55–71) | 0.85 |
SOFA admission | 7.0 (5.0–8.2) | 5.0 (3.5–7.0) | 0.007 |
Use of vasopressor | 27 (90%) | 8 (27.6%) | < 0.001 |
Use of ATB | 28 (93.3%) | 25 (86.2%) | 0.36 |
Use of ATF | 24 (80 %) | 22 (75.9%) | 0.70 |
Use of corticosteroids | 10 (33.3%) | 13 (44.9%) | 0.36 |
NT-proBNP | 3255 (1055–13727) | 4650 (1440–11905) | 0.516 |
Comorbidities | |||
COPD | 4 (13.3%) | 2 (6.9%) | 0.42 |
HF | 3 (10%) | 7 (24.1%) | 0.14 |
Follow-up data | |||
HD | 3 (10%) | 2 (6.9%) | 0.66 |
CT | 17 (56.7%) | 12 (40%) | 0.24 |
Exclusive palliative care | 2 (6.7%) | 6 (20.7%) | 0.11 |